首页 | 本学科首页   官方微博 | 高级检索  
检索        


Anticholinergic burden of long-term medication is an independent risk factor for the development of postoperative delirium: A clinical trial
Institution:1. Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany;2. Cooperation Unit Clinical Pharmacy, University of Heidelberg, Heidelberg, Germany;3. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany;4. Network Ageing Research, University of Heidelberg, Heidelberg, Germany;5. Institute of Health Care and Social Sciences, FOM University, Essen, Germany
Abstract:BackgroundPostoperative delirium (POD) is a common complication after surgery.ObjectiveWe sought to determine the association between preoperative anticholinergic load calculated using the anticholinergic drug scale (ADS) and POD in cancer patients over 65 years of age.DesignA retrospective sub-investigation of a randomised controlled interventional trial.SettingTwo tertiary university hospitals.PatientsOverall, patients aged 65 years and older scheduled for surgical treatment of gastrointestinary, genitourinary or gynaecological cancers.Main outcome measuresThe primary outcome was the interaction between anticholinergic drug scale and occurrence of postoperative delirium. Patient clinical parameters and ADS scores were assessed preoperatively. POD screening was conducted for a total of 7 days following surgery using validated measures. Independent associations between ADS and POD were assessed using multivariate logistical regression analyses.ResultsA total of 651 patients (mean age, 71.8 years; 68.5% males) were included. Of those, 66 patients (10.1%) developed POD. The ADS score was independently associated with the occurrence of POD (higher ADS per point OR 1.496; 95% CI 1.09–2.05; p = 0.01). Additionally, age (per year OR 1.06; CI 95% CI 1.01–1.11; p = 0.03) and ASA state (OR 2.16; 95% CI 1.22–3.83; p = 0.01), as well as stay on ICU (yes vs. no OR 2.8; 95% CI 1.57–4.998; p < 0.01), were independently associated with POD.ConclusionsADS assessment according to chronic medication use is a cost-effective, non-invasive method of identifying elderly cancer patients at risk for POD.Trial registry: www.clinicaltrials.gov. Identifier NCT01278537.Ethics: IRB of Charité University-Medicine Berlin, Germany; EA2/241/08.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号